CTI BioPharma announces United Kingdom NCRI AML Cooperative Group advances tosedostat
CTI BioPharma announced the UK's NCRI Oncology Clinical Studies Group has chosen to advance tosedostat, the Company's investigative oral aminopeptidase inhibitor, to the second stage of a randomized clinical trial of low-dose cytarabine in older patients with AML. November 24, 2015